Sugi Predict

Sugi Predict / Compounds / SCHEMBL4085697

SCHEMBL4085697

SCHEMBL4085697

COc1ccc2cc(-c3n[nH]c4ccc(-c5n[nH]c(CN6CCCC6C)n5)cc34)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1D P48730 1/20 0.51
▸ HRH3 Q9Y5N1 6/20 0.46
▸ ADORA2A P29274 1/20 0.44
▸ LRRK2 Q5S007 5/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ PRKD3 O94806 1/20 0.37
▸ PRKCG P05129 1/20 0.37
▸ PHKG2 P15735 1/20 0.37
▸ RPS6KB1 P23443 1/20 0.37
▸ MARK3 P27448 1/20 0.37
▸ PRKCI P41743 1/20 0.37
▸ CLK2 P49760 1/20 0.37
▸ IRAK1 P51617 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080101 0.97 CSNK1D (0.52) CSNK1DHRH3ADORA2ALRRK2MEN1
SCHEMBL4080007 0.90 CSNK1D (0.49) CSNK1DHRH3ADORA2ALRRK2KMT2A
SCHEMBL4080009 0.90 CSNK1D (0.49) CSNK1DHRH3ADORA2ALRRK2KMT2A
SCHEMBL5246773 0.86 CSNK1D (0.68) CSNK1DHRH3ADORA2ALRRK2CLK1
SCHEMBL4090371 0.85 CSNK1D (0.67) CSNK1DHRH3ADORA2ALRRK2CLK1
SCHEMBL4083423 0.84 CSNK1D (0.66) CSNK1DHRH3ADORA2ALRRK2CLK1
SCHEMBL5378078 0.84 CSNK1D (0.71) CSNK1DHRH3MEN1KMT2ACLK2
SCHEMBL4084738 0.84 CSNK1D (0.65) CSNK1DHRH3ADORA2ALRRK2CLK1
SCHEMBL13812173 0.83 CSNK1D (0.56) CSNK1DHRH3CLK1JAK2PRKD3
SCHEMBL4084893 0.82 ADORA2A (0.52) CSNK1DADORA2ALRRK2CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885HRH3 2504/4885ADORA2A 1535/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885HRH3 2769/4885ADORA2A 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.